Trial Profile

A Phase IB Study FOLFIRINOX and NIS793 in Patients With Pancreatic Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 16 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Nisevokitug (Primary) ; Oxaliplatin (Primary) ; Capecitabine
Indications Adenocarcinoma; Adenosquamous carcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Therapeutic Use

Most Recent Events

25 Jun 2024 Status changed from recruiting to discontinued. (Reason the study was stopped: NIS793 is no longer being developed.)
21 Jan 2023 Trial design presented at the 2023 Gastrointestinal Cancers Symposium
19 Aug 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com